Shares of Can-Fite BioPharma Ltd. (CANF) are soaring about 92 percent on Wednesday morning trading following the announcement of results from its Phase IIa open-label study evaluating namodenoson in patients with advanced pancreatic ductal adenocarcinoma.
The company's shares are currently trading at $9.62 on the New York Stock Exchange, up 92.40 percent. The stock opened at $8.66 and has climbed as high as $10.40 so far in today's session. Over the past year, it has traded in a range of $3.40 to $46.60.
The study met its primary endpoint, which was safety, demonstrating that namodenoson was very well tolerated in this heavily pretreated patient population.
For comments and feedback contact: editorial@rttnews.com
Business News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.